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Background: Many studies have demonstrated genetic and environmental factors that lead to renal cell carcinoma
(RCC) and that occur during a protracted period of tumourigenesis. It appears suitable to identify and characterise
potential molecular markers that appear during tumourigenesis and that might provide rapid and effective
possibilities for the early detection of RCC. EGFR activation induces cell cycle progression, inhibition of apoptosis
and angiogenesis, promotion of invasion/metastasis, and other tumour promoting activities. Over-expression of
EGFR is thought to play an important role in tumour initiation and progression of RCC because up-regulation of
EGFR has been associated with high grade cancers and a worse prognosis.
Methods: Characterisation of the protein profile interacting with EGFR was performed using the following: an
immunohistochemical (IHC) study of EGFR, a comprehensive computational study of EGFR protein-protein
interactions, an analysis correlating the expression levels of EGFR with other significant markers in the
tumourigenicity of RCC, and finally, an analysis of the utility of EGFR for prognosis in a cohort of patients with renal
cell carcinoma.
Results: The cases that showed a higher level of this protein fell within the clear cell histological subtype
(p = 0.001). The EGFR significance statistic was found with respect to a worse prognosis. In vivo significant
correlations were found with PDGFR-β, Flk-1, Hif1-α, proteins related to differentiation (such as DLL3 and DLL4
ligands), and certain metabolic proteins such as Glut5. In silico significant associations gave us a panel of 32
EGFR-interacting proteins (EIP) using the APID and STRING databases.
Conclusions: This work summarises the multifaceted role of EGFR in the pathology of RCC, and it identifies EIPs
that could help to provide mechanistic explanations for the different behaviours observed in tumours.
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The ErbB family of receptor tyrosine kinases (RTKs) cou-
ples the binding of extracellular growth factor ligands to
intracellular signalling pathways regulating diverse bio-
logical responses, including proliferation, differentiation,
cell motility, and survival. Ligand binding to the four
closely related members of this RTK family—epidermal
growth factor receptor (EGFR, also known as ErbB-1 or
HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4* Correspondence: vanessa.medina.villaamil@sergas.es
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distribution, and reproduction in any medium(HER4)—induces the formation of receptor homo- and
hetero-dimers and the activation of the intrinsic kinase
domain.
The Shc- and/or Grb2-activated mitogen-activated
protein kinase (MAPK) pathway is a common target
downstream of all of the ErbB receptors. Similarly, the
phosphatidylinositol-3-kinase (PI-3 K) pathway is dir-
ectly or indirectly activated by most of the ErbBs. Sev-
eral cytoplasmic docking proteins appear to be recruited
by specific ErbB receptors and are less exploited by
others. These include the adaptors Crk and Nck, the
phospholipase C gamma (PLCgamma), the intracellulard Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ligase [1].
EGFR signalling cascade is one of the best studied and
most important signalling pathways in mammals. This
pathway regulates cell growth, survival, proliferation and
differentiation (Figure 1). EGFR signalling is critically
involved in renal organogenesis and electrolyte homeo-
stasis [2].
Multiple studies have shown over-expression of the
EGFR receptor in renal cell carcinoma (RCC) compared
with normal renal tissue, and EGFR expression in RCC
was localized to the cell membrane, whereas the EGFR
expression in normal kidney tissues was chiefly observed
in the cytoplasm, and this different location of EGFR ex-
pression could be associated with human renal tumouro-
genesis [3]. EGFR over-expression is thought to play an
important role in tumour initiation and progression of
RCC because the up-regulation of EGFR has been asso-
ciated with a high grade and a worse prognosis [4].
Moreover, clear-cell RCC is frequently associated with
the loss of von Hippel-Lindau (VHL) tumour suppressor
gene function, which results in the aberrant transcrip-
tional activation of genes that contribute to tumourFigure 1 ERBB Pathway. The ERBB Signalling Pathway obtained from thegrowth and metastasis. Tumour hypoxia, independent of
VHL loss of function, increases EGFR expression through
early growth response factor 1 (Egr-1) [5].
Despite some great successes, many human diseases
cannot yet be effectively treated, prevented or cured.
Hence, there is a need to investigate the molecular basis
of these diseases in more detail. For this purpose, rele-
vant biomedical data must be gathered, integrated and
analysed in a meaningful way. Mechanistic understand-
ing requires the integration of all of the information that
is available about the involved key players and how they
interact within the cell. These interactions are typically
represented by means of biological networks. The bio-
logical context in which disease-related genes operate
must be considered. Many human diseases cannot be
attributed to the malfunction of single genes but instead
arise from complex interactions among multiple genetic
variants [6]. Hence, to understand disease mechanisms,
a network of key players that are related to the disease
and their interactions, for example through biological
pathways, must be considered. A biological pathway can
circumscribe several types of biological processes, in-
cluding regulatory, metabolic and signalling processes orKyoto Encyclopedia of Genes and Genomes (KEGG).
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work is to probe in-depth into the EGFR signalling path-
way and EGFR PPIs in an RCC population. Although
several bioinformatic studies have been undertaken for
similar purposes [7-9], we consider that more effort
based on validated experimental information is needed
to improve the quality of the PPIs that can be obtained
from the interactome networks.Materials and methods
Case selection
The patient cohort included 80 patients who were trea-
ted with a partial or radical nephrectomy for RCC, in-
cluding chromophobe RCC (chRCC), papillary RCC
(pRCC) and clear-cell RCC (cRCC) variants, and who
were recruited between 1996 and 2006. Immunohisto-
chemistry (IHC) studies were performed and clinical
data from an established kidney cancer database were
reviewed. The Institutional Review Board of Modelo
Hospital approved the retrospective review of the med-
ical records and the use of archived tumour specimens.Immunohistochemistry tissue array analysis related to
renal cell carcinoma
All of the archival tissue samples were routinely stored
in formalin and were embedded in paraffin. The repre-
sentative tissue areas were marked on standard
hematoxylin and eosin (H&E) sections, were punched
out of the paraffin block using a 2.0-mm punch and
were inserted in a recipient paraffin block to produce
a 6x8 array of 48 cases. A normal cerebellum tissue
sample was inserted as a negative control. When pos-
sible, triplicate cores per specimen were arrayed on a
recipient paraffin block to decrease the error that was
introduced by sampling and to minimise the impact
on the tissue during processing. Sections (4 μm) were
cut from the completed array blocks and were trans-
ferred to silanised glass slides. The primary antibodies
used are listed in Table 1. The immunohistochemistry
(IHC) technique was conducted, as previously
described [10]. The expression was evaluated in a
blinded fashion to validate the diagnostic morphology
of each array spot. The evaluation of the expression
involved the site and the degree of reactivity. The site
of the reactivity included the evaluation of the relevant
histological subtype as well as the subcellular localisa-
tion. The degree of reactivity included the evaluation
of the maximal staining intensity using a 0 to 3 scale
(0, negative; 1, weak; 2, moderate; 3, strong) as well as
the percentage of positive cells at each stated intensity.
The pathological variables that were studied are listed
in Table 2.PPI resources
One of the most productive areas of current research is
the area of protein-protein interactions and interactome
data [11]. Data about the interaction of two or more
proteins come either from small-scale experimental
work or from large-scale experimental methods. Protein
interaction resources include the following 2 databases:
1. Agile Protein Interaction DataAnalyser (APID) [12]:
developed to better assess the quality of the PPI data
and to provide a more comprehensive integration of
the main currently known PPI interactions. APID
integrates data coming from five main source
databases: BIND [13], DIP [14], HPRD (Human
protein reference database) [15], IntAct (Database
system and analysis tools for protein interaction data)
[16] and MINT (Molecular Interactions Database) [17].
2. Search Tool for the Retrieval of Interacting Genes
(STRING) [18]: an update to provide all of the
information on functional links between proteins.
The main strengths of STRING lie in its unique
comprehensiveness, its confidence scoring and its
interactive and intuitive user interface. All of the
associations in STRING are provided with a
probabilistic confidence score, which is derived by
separate groups of associations from the manually
curated functional classification scheme of the KEGG
database [19].
Human EGFR protein network prediction
Predictions of EPI have been attached to obtain
insights about mechanisms of disease development and
to find key proteins that are related to a disease or a
biological pathway [20]. There are computational tools
to predict PPIs, such as gene neighbourhood [21], gene
fusion [22], phylogenetic profile [23], and interolog
[24]. In the interolog approach, the interaction of 2
query proteins is predicted when both have homolo-
gous proteins that are already known to interact [20].
We performed a STRING search in the protein mode.
The prediction methods that were activated are the fol-
lowing: neighbourhood, gene fusion, co-occurrence, co-
expression, experiments, databases, text mining and
homology. The number of associations stored in
STRING was shown separately for each data source and
confidence range (low: scores < 0.4, medium: scores from
0.4 to 0.7, and high: scores > 0.7). Only those with a high
confidence were accepted.
Statistical analysis methods
Data are expressed as the mean± the standard devi-
ation (SD). The non-normality of the distribution of the
protein expression values was assessed by the Kolmogorov-
Smirnov test. Thus, non-parametric statistics (Mann–
Table 1 List of antibodies
ANTIBODY & EGFR correlation p-value COMPANY DILUTION PRETREATMENT POSITIVE CONTROL
Hif1-α (p = 0.046) Abcam 1:1500 Citrate Squamous cell Carcinoma
VHL (p = 0.114) ABR Ready to use Citrate Healthy Kidney
VEGF (p = 0.755) Sta Cruz 1:100 Citrate Healthy Kidney
Flk-1 (p = 0.001) Sta Cruz 1:50 Citrate Healthy Kidney
CAIX (p = 0.538) Abcam 1:500 Citrate Renal cell carcinoma
EGFR Dako 1:25 Proteinase K Squamous cell Carcinoma
PDGFR-α (p = 0.320) Sta Cruz 1:200 Citrate Ovarian Carcinoma
PDGFR-β (p = 0.000) Serotec 1:40 EDTA Breast Carcinoma
TGF-α (p = 0.260) LabVision Ready to use Citrate Anterior Pituitary
TGF-β (p = 0.456) Millipore 1:500 Citrate Colon Carcinoma
C-KIT (p = 0.182) Dako 1:50 No required GIST
NOTCH1 (p = 0.052) Abcam 3ug/ml Citrate Healthy Kidney
NOTCH2 (p = 0.937) Lifespan 1:250 Citrate Healthy Kidney
NOTCH3 (p = 0.249) Sta Cruz 1:50 Citrate Healthy Kidney
NOTCH4 (p = 0.337) Sta Cruz 1:100 Citrate Healthy Kidney
JAGGED1 (p = 0.058) Sta Cruz 1:50 EDTA Astrocytoma
DLL1 (p = 0.175) Serotec 10ug/ml EDTA Healthy Kidney
DLL3 (p = 0.049) Aviva 15ug/ml Citrate Healthy Kidney
DLL4 (p = 0.046) Serotec 10ug/ml Citrate Healthy Kidney
p53 (p = 0.696) Dako 1:50 EDTA Breast Carcinoma
BAX (p = 0.077) Abcam Ready to use EDTA Amygdala
MDM2 (p = 0.394) Abcam 1.5ug/ml Citrate Squamous cell Carcinoma
Survivin (p = 0.218) Sta Cruz 1:100 Citrate Breast Carcinoma
BCL2 (p= 0.000) Dako 1:75 EDTA Amygdala
Glut-1 (p = 0.296) Abcam Ready to use Citrate Healthy Esophagous
Glut-2 (p = 0.328) Sta Cruz 1:50 Citrate Liver
Glut-3 (p = 0.529) Abcam 1:25 Citrate Placenta
Glut-4 (p = 0.933) Abcam 1:250 Citrate Hearth
Glut-5 (p =0.006) Abcam 1:250 Citrate Healthy Small intestine
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the potential correlation between protein expression and
the pathological features of the study subjects. P values<0.05
were considered to be significant. The standard Pearson
correlation values for IHC data of the molecular factors
studied were calculated. All of the statistical analyses
were performed using commercially available software
(SPSS 19.0 for Windows).
Results
Immunohistochemical staining of EGFR and its correlation
with pathological variables
The cases that showed higher membranous positivity for
this protein were those falling within the clear cell histo-
logical subtype (p = 0.001). Those cases expressing more
EGFR were consistent with pathological features asso-
ciated with a worse prognosis: pelvic (p = 0.014), and
lymphatic vessels invasion (p = 0.040), rupture of the
renal capsule (p = 0.008), renal hilar invasion (p = 0.029)and greater node involvement (p = 0.001). We found no
statistical support to associate this protein with other
pathological variables that were analysed.
The correlation of EGFR protein with other markers
The statistical significance values of correlations between
molecular variables are listed in Figure 2. The analysis of
the relationship between EGFR and a panel of relevant
RCC tumour markers (see Table 1) revealed a signifi-
cant correlation with receptor tyrosine kinases, such as
vascular endothelial growth factor receptor 2 (Flk1) and
platelet derived growth factor receptor beta (PDGFR-β),
hypoxia-inducible factor 1-alpha (Hif1-α), apoptosis
regulator Bcl-2 (Bcl-2), proteins related to differentiation,
such as delta-like protein 3 and 4 (DLL3 and DLL4), and
proteins related to fructose uptake such as facilitated
fructose transporter, member 5 (Glut5). Our results indi-
cate that EGFR is statistically significantly associated with
7 of the 29 molecules studied, an increase or decrease of
Table 2 Pathological variables analysed in this study
PATHOLOGICAL PATIENTS RELATED MARKER
VARIABLES NUMBER N=80
Differentiation degree (Fuhrman Grade)
Well 15 (18.75%)
Moderate 45 (56,25%)
Poor 16 (20%)
Undifferentiated 4 (5%) EGFR p = 0.081
Pelvis invasion
Yes 9 (11,25%) EGFR p = 0.014
No 66 (82,5%)
Undetermined 5 6,25%)
Breaking capsule
Yes 12 (15%) EGFR p = 0.008
No 64 (80%)
Undetermined 4 (5%)
Tumor depth
1 63 (78,75%)
2 4 (5%)
3 12 (15%) EGFR p = 0.833
4 1 (1,25%)
Histology type
Clear cell 57 (71,25%) EGFR p = 0.001
Papillary 6 (7,5%)
Chromophobe 15 (18,75%)
Undetermined 2 (2,5%)
Tumor localization
Right 40 (50%) EGFR p = 0.275
Left 39 (48,75%)
Undetermined 1 (1,25%)
Veins invasion
Yes 9 (11,25%) EGFR p = 0.475
No 67 (83,75%)
Undetermined 4 (5%)
Lymphatic vessels invasion
Yes 2 (2,5%) EGFR p = 0.040
No 78 (97,5%)
Hilar invasion
Yes 6 (7,5%) EGFR p = 0.029
No 68 (85%)
Undetermined 6 (7,5%)
Node involvement
0 19 (23,75%)
1–5 59 (73,75%)
>5 2 (2,5%) EGFR p = 0.000
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of each of the following 7 proteins.. The Pearson statistic
indicated that the strongest positive association is found
with the fructose transporter Glut5 followed by Hif1-α
and the ligands DLL4 and DLL3, all of which had Pear-
son values that were very similar and indicative of a
weaker association. On the other hand, the Pearson stat-
istic showed a strong negative trend of association be-
tween EGFR and the growth factor PDGFR-β followed by
the anti-apoptotic Bcl-2, finally EGFR displayed a moder-
ate negative association with Flk1. Figure 2 shows the
IHQ expression of EGFR and the associated proteins
with Pearson statistic values.
PPI by APID
The starting query EGFR_HUMAN gave us a sample
table with only one row because only one protein was
found. The program displayed 282 proteins that interact
with EGFR (Figure 3). The selectors presented allow us
to filter the data to choose only the interactions that are
validated by at least a certain number of experiments
that prove a protein-protein interaction, or to filter the
data to choose only the interactions that are supported
by the presence in the protein pair of two Pfam domains
that are known to interact according to the 3D struc-
tural interaction database iPfam. With the intention of
tightening the search, we stayed with only those interac-
tions that were verified by more than three experiments
and that had iPfam validation. In this way, the number
of interaction partners for EGFR was reduced to only 21
proteins, which are detailed in Table 3. Thus, we can say
that the growth factor receptor-bound protein 2 (GRB2),
epidermal growth factor (EGF), (Src homology 2 domain
containing) transforming protein 1 (SHC1), Ras GTPase-
activating protein 1 (RASA1), Proto-oncogene C-crk
(CRK) and 1-phosphatidylinositol-4,5-bisphosphate phos-
phodiesterase gamma-1 (PLCG1) proteins are the most
experimentally studied proteins in relation to EGFR in-
teractions, which has allowed us to improve our know-
ledge of the EGFR interactome network.
PPI by STRING
The EGFR protein network obtained from the STRING
database was formed for the next proteins: EGF, GRB2,
SHC1, cas-Br-M (murine) ecotropic retroviral transform-
ing sequence (CBL), transforming growth factor alpha
(TGFA), protein tyrosine phosphatase, non-receptor type
1 (PTPN1), signal transducer and activator of transcrip-
tion 3 (acute-phase response factor) (STAT3), ubiquitin
C (UBC), v-erb-b2 erythroblastic leukemia viral onco-
gene homolog 2 (ERBB2), phospholipase C, gamma 1
(PLCG1), ERBB receptor feedback inhibitor 1 (ERRFI1),
epidermal growth factor receptor pathway substrate 15
(EPS15), protein tyrosine phospatase, non-receptor type
Figure 2 Immunohistochemistry of those EGFRs that are statistically associated proteins. Proteins with statistically significant associations
are represented with their statistical values (Pearson correlation and p-value associated) and by immunohistochemistry staining.
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oncogene homolog (avian) (SRC), son of sevenless
homolog 1 (Drosophila) (SOS1), epiregulin (EREG),
betacellulin (BTC), signal transducer and activator of
transcription 1 (STAT1), NCK adaptor protein 1 (NCK1)
and protein tyrosine phosphates, non-receptor type 6
(PTPN6). All of these proteins had the required con-
fidence (score) higher than 0.7, and no more than 20
interactors were shown. Figure 4 shows the STRING EIP
network. Table 4 shows the data scores for the
interactors.
Discussion
The majority of human epithelial cancers are marked by
the activation of EGFR, which was the first growth factor
receptor to be proposed as a target for cancer therapy.
Dysregulation of EGFR is often observed in association
with carcinogenesis, which can be caused by receptor
over-expression, mutations or deletions [25]. A blockade
of EGFR results in the inhibition of growth in several
human carcinoma cell lines [26]. Over-expression of
EGFR and its family members have been found in the
majority of human cancers. Cancer patients with EGFR
over-expression often have a worse prognosis [27]. Themajority of human carcinomas can synthesise and se-
crete EGF-like growth factors that can bind to ErbB
receptors expressed in accessory cells of the tumour
microenvironment [28]. This interaction has been shown
to regulate important mechanisms of tumour progres-
sion, such as the proliferation and motility of endothelial
cells and the production of pro-angiogenic and proos-
teoclastogenic cytokines in tumour and stromal cells.
This observation of EGFR makes an interesting target
for therapeutic intervention even in tumours with EGFR-
independent growth. Interestingly, the clinical activity of
anti-EGFR agents in patients carrying EGFR-negative
tumours has already been demonstrated [29].
Our tissue array study demonstrated that the increased
expression of EGFR was a dependent predictor of a
worse prognosis for patients with RCC. Moreover, in-
creased EGFR staining was associated with the clear cell
histological subtype. Our results were identical with pre-
vious studies that showed that a higher expression of
membranous EGFR was frequently detected [27].
Previous studies have shown EGFR over-expression in
the advanced stage, poor prognosis and metastatic
human cancer [30]. Over-expression of EGFR played an
important role in tumour initiation and progression of
Figure 3 APID Network. Proteins displayed by APID without filters. Proteins are more or less close to EGFR according to their cluster coefficient.
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with high-grade tumours and a worse prognosis [31].
The prognostic association of EGFR over-expression in
RCC, however, is a controversial issue. Some studies
showed an association of EGFR immunoreactivity with
well differentiated RCCs [32] or regarded strong mem-
branous EGFR immunostaining as an indicator of good
prognosis [33], whereas others showed an association of
EGFR immunoreactivity with high tumour stage/grade
and poor prognosis [34] or showed no significant asso-
ciations at all [35]. As expected from previous studies
[27], our study showed that there was a significant cor-
relation between the level of membranous EGFR expres-
sion and the histologic subtype, with a higher expression
in conventional RCC compared to non-conventional
RCC (including papillary and chromophobe).
Biostatistical analysis of the IHC scores obtained from
29 markers studied in samples of patients affected by
renal tumours gave us an EGFR positive association, an
increase of EGFR means an increase in the next proteinsand vice versa, with Hif1-α, DLL3, DLL4 and Glut5 and
an EGFR negative association, an increase of EGFR
means a decrease in the next proteins and vice versa,
with Flk1, Bcl-2 and PDGFR-β.
Previous studies in RCC cells link HIF activation with
the aberrant production of a bona fide mitogen of renal
epithelial cells and provide evidence for a role of HIF in
the initiation of tumourigenesis [36].
The Notch pathway plays a central role in stem cell
maintenance, cell fate decisions, and cell survival. Four
members of the Notch family have been identified, each
a single-pass transmembrane protein with complex ex-
tracellular and intracellular domains. The binding of a
Delta-like (DLL1, DLL3 and DLL4 studied in this work)
or Jagged (Jagged1) ligand on one cell to Notch on an
adjacent cell triggers enzymatic cleavages, which liberate
the Notch intracellular domain. We demonstrated previ-
ously the presence of Notch1-4 and its ligands DLL1,
DLL3, DLL4 and Jagged1 in RCC and their import-
ance [37]. No previous report to our knowledge has
Table 3 EGFR interaction partners obtained by APID
PROTEIN INTERACTORS EXPERIMENTS PROVENANCE CLUSTER COEFFICIENT
EGFR_HUMAN/GRB2_HUMAN 18 BIND - HPRD - IntAct - MINT - BioGRID 0.018153
EGF_HUMAN/EGFR_HUMAN 15 BIND - DIP - HPRD - IntAct - MINT - BioGRID 0.242424
EGFR_HUMAN/SHC1_HUMAN 12 BIND - DIP - HPRD - IntAct - MINT - BioGRID 0.100999
PTN1_HUMAN/EGFR_HUMAN 9 HPRD - MINT - BioGRID 0.070715
EGFR_HUMAN/RASA1_HUMAN 7 BIND - HPRD - MINT - BioGRID 0.122177
CRK_HUMAN/EGFR_HUMAN 6 HPRD - MINT - BioGRID 0.049001
SRC_HUMAN/EGFR_HUMAN 5 HPRD - MINT - BioGRID 0.033376
PLCG1_HUMAN/EGFR_HUMAN 5 BIND - HPRD - MINT - BioGRID 0.064601
EGFR_HUMAN/STAT3_HUMAN 4 BIND - HPRD - IntAct - BioGRID 0.078719
EGFR_HUMAN/JAK2_HUMAN 4 HPRD - MINT - BioGRID 0.117345
NCK1_HUMAN/EGFR_HUMAN 4 HPRD - MINT - BioGRID 0.022317
GRB10_HUMAN/EGFR_HUMAN 4 HPRD - MINT - BioGRID 0.22792
TGFA_HUMAN/EGFR_HUMAN 3 BIND - DIP - HPRD - IntAct - BioGRID 0.044118
PTN11_HUMAN/EGFR_HUMAN 3 HPRD - MINT - BioGRID 0.09284
SH3K1_HUMAN/EGFR_HUMAN 3 HPRD - MINT - BioGRID 0.108213
P85A_HUMAN/EGFR_HUMAN 3 BIND - HPRD - MINT 0.047572
EGFR_HUMAN/STAT1_HUMAN 3 HPRD - BioGRID 0.080438
EGFR_HUMAN/VAV2_HUMAN 3 HPRD - BioGRID 0.235294
EGFR_HUMAN/STA5A_HUMAN 3 HPRD - BioGRID 0.193759
SOS1_HUMAN/EGFR_HUMAN 3 HPRD - BioGRID 0.155465
EGFR_HUMAN/PTN6_HUMAN 3 HPRD - BioGRID 0.101232
The table shows 21 proteins with greater evidence for EIP (EGFR interacting proteins). The cluster coefficient, a graph parameter that indicates the degree of
inter-connection of the group of proteins directly interact to a query protein, in our case, EGFR. A cluster coefficient value close to zero indicates that the protein
pair is very close, a value away from zero shows that the protein pair is farthest.
Figure 4 STRING Network. EGFR interacting protein network obtained by STRING. This view is the confidence view. Stronger associations are
represented by thicker lines.
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Table 4 EGFR scores for the interactors obtained by
STRING
Node 1 Node 2
Combined score
Node 1 Node 2
Combined score
UBC PLCG1 0.845 SOS1 PTPN11 0.999
*STAT1 EGFR 0.998 SHC1 PTPN1 0.920
SOS1 GRB2 0.999 PTPN6 EGFR 0.998
GRB2 PLCG1 0.992 EGFR *PLCG1 0.999
EPS15 EGF 0.983 SRC ERBB2 0.855
EGF STAT3 0.996 PTPN1 STAT3 0.966
ERRFI1 EGF 0.956 SRC EGF 0.999
PTPN1 EGFR 0.999 STAT1 STAT3 0.996
BTC ERBB2 0.990 ERBB2 EGF 0.999
UBC EGF 0.922 GRB2 CBL 0.999
SRC PLCG1 0.989 SHC1 STAT3 0.869
SRC NCK1 0.931 NCK1 CBL 0.948
ERBB2 EREG 0.966 SOS1 CBL 0.972
GRB2 ERBB2 0.999 EPS15 GRB2 0.992
EPS15 EGFR 0.999 EGFR *STAT3 0.999
SHC1 TGFA 0.724 SRC GRB2 0.992
EGF CBL 0.980 PTPN6 STAT1 0.781
SOS1 SRC 0.986 EGFR EREG 0.999
GRB2 STAT3 0.973 SHC1 SRC 0.806
GRB2 EGF 0.998 *GRB2 EGFR 0.999
PTPN6 CBL 0.714 ERRFI1 ERBB2 0.933
SHC1 PLCG1 0.913 EPS15 UBC 0.995
PTPN1 SRC 0.999 CBL PLCG1 0.999
SHC1 ERBB2 0.998 PTPN1 ERBB2 0.884
PTPN11 ERBB2 0.990 SHC1 PTPN6 0.766
EGFR *EGF 0.999 SHC1 CBL 0.999
TGFA ERBB2 0.992 PTPN11 CBL 0.960
EGFR CBL 0.999 PTPN6 GRB2 0.969
NCK1 PLCG1 0.708 ERRFI1 EGFR 0.999
PTPN1 GRB2 0.999 PTPN6 EGF 0.976
PTPN11 GRB2 0.999 *SRC EGFR 0.999
SHC1 EGF 0.996 SOS1 ERBB2 0.961
SRC STAT3 0.999 STAT1 PTPN11 0.998
NCK1 EGF 0.979 SHC1 PTPN11 0.971
EGFR ERBB2 0.999 STAT1 SRC 0.992
SRC PTPN11 0.802 PTPN11 EGF 0.996
*SOS1 EGFR 0.999 EPS15 SRC 0.807
SOS1 PLCG1 0.943 SHC1 STAT1 0.830
PTPN6 STAT3 0.893
PTPN11 PLCG1 0.727
PTPN11 STAT3 0.988
UBC EGFR 0.999
UBC CBL 0.995
ERBB2 PLCG1 0.982
EGF PLCG1 0.981
Table 4 EGFR scores for the interactors obtained by
STRING (Continued)
EPS15 CBL 0.960
ERBB2 STAT3 0.989
PTPN1 EGF 0.979
PTPN6 PTPN11 0.961
SHC1 EGFR 0.999
PTPN6 SRC 0.780
BTC EGFR 0.999
*PTPN11 EGFR 0.999
SOS1 NCK1 0.998
STAT1 EGF 0.995
*NCK1 EGFR 0.998
*TGFA EGFR 0.999
SOS1 EGF 0.971
SRC CBL 0.998
SHC1 SOS1 0.999
SHC1 GRB2 0.999
The table shows all associations in STRING provided with a probabilistic
confidence score for EIP and between proteins belongs to this EGFR
interactome network. Each node represents a protein which by edges may be
interacting with any other. Each score represents a rough estimate of how
likely a given association describes a functional linkage between two proteins
that is at least as specific as that between an average pair of proteins
annotated on the same ‘map’ or ‘pathway’ in KEGG. *Proteins showed by
STRING and APID as EIP.
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pression with increased EGFR. Precedent reports [38] in-
dicate that Notch signalling can have very different
outputs depending on whether the ligands are binding,
and this difference could be one explanation for context
dependence. It has previously been found that Notch ac-
tivation is key to maintaining Ras pathway activity, one
of the downstream mediators of EGFR [39]. The Notch
pathway is ubiquitous in development and cell fate de-
termination, and EGFR plays roles in development as
well. This report suggests that EGFR is an intermediate
of some of the many roles of Notch in development. It
also bases another point of cross talk between the Notch
and EGFR–Ras pathways.
Previous studies [40] from our group showed that
Glut5 expression associates more strongly with the clear
cell RCC subtype. The clear cell subtype of RCC is char-
acterised histologically by a distinctive pale, glassy cyto-
plasm, and this appearance of clear cell RCC is from
abnormalities in the carbohydrate and lipid metabolism;
these abnormalities result in glycogen and sterol storage.
These data suggest a role for the Glut5 isoform in fruc-
tose uptake that takes place in clear cell RCC cells and
that subsequently leads to the malignant RCC progres-
sion. Here, we analysed for the first time a possible link
between fructose metabolism and cell proliferation,
which is understood to be an over-expression of EGFR
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same histological subtype (clear cell RCC), which shows
an increase in the metabolic rate by fructose intake in
cells that proliferate more.
Interestingly, further analysis revealed an inverse cor-
relation between EGFR and the vascular endothelial
growth factor receptor 2, Flk1. The amounts of Flk1, as
determined by IHC, were greatly reduced in those RCC
samples with higher EGFR staining. Dysregulation of
angiogenesis is implicated in the development of many
human cancers, especially in clear cell RCC, a highly
vascularised tumour. Our findings could show a negative
feedback loop at certain times in those tumoural renal
cells with EGFR excess, which leads to a decrease in
angiogenesis through a decreased expression of Flk1.
The signal transduction pathways activated by the
PDGFR-β are well characterised and resemble those of
other receptor tyrosine kinases such as EGFR and the
vascular endothelial growth factor receptor. Following
its activation, the PDGFR-β stimulates intracellular sig-
nalling proteins that include Ras-MAPK, phosphatidyli-
nositol 3-kinase, phospholipase Cγ, and ERK1/2 [41].
An explanation for this fact could be that those cells with
activated EGFR pathway proliferation could have an atte-
nuated proliferation pathway through PDGFR-β, resulting
in decreased angiogenesis and autocrine growth stimula-
tion. Apoptosis is a genetically controlled mechanism of
cell death that is involved in the regulation of tissue
homeostasis. Bcl-2 antagonises p53-induced apoptosis
and can contribute to chemoresistance [42]. The percent-
age of cells stained was the greatest in the cases that did
not have EGFR staining.
The main limitation of our work is that the approach
to the expression of selected markers by means of a tis-
sue array study and IHC has not been combined with
molecular biology techniques, such as immunoprecipita-
tion or western blotting. We used IHC of primary tu-
mours from patients to demonstrate for the first time
the relevant interactions that are involved in different
pathways that regulate RCC cell fates.
The models of EIP by STRING suggest valuable inter-
relations. In the analysis of putative interactors of EGFR
based on the score value, the lowest score value of 0.708
was observed for nodes NCK1 and PLCG1, and different
nodes were shown, with the highest score being 0.999.
The proteins with high score values exhibit a higher af-
finity for EGFR than low-score proteins (Table 4).
The results are convincing because the data are taken
from different species and are based on a variety of ex-
perimental methods, such as yeast-two-hybrid, X-ray
crystallography, mass spectroscopy, and affinity purifica-
tion. The list of proteins obtained by STRING could
form a variety of functional connections with each other,
including stable complexes, metabolic pathways and abewildering array of direct and indirect regulatory inter-
actions in our cohort of renal tumours. These connec-
tions can be conceptualised as networks, and the size
and complex organisation of these networks present a
unique opportunity to view a given genome as some-
thing more than just a static collection of distinct genetic
functions. The ‘network view’ of a genome is increasingly
used in many areas of applied biology: protein networks
are used to increase the statistical power of human gen-
etics, to aid in drug discovery, to close gaps in metabolic
enzyme knowledge and to predict phenotypes and gene
functions, to name a few examples [43].
STRING is by no means the only such site: APID
enabled us to reduce to 21 the number of EIPs demon-
strated by specific small-scale or large-scale experimen-
tal methods.
An important next step would be to discover new EIPs
that could be extracted from in vitro biological net-
works, such as those that validate, with experimental
data from the laboratory, the behaviour of the computa-
tional network model obtained for EGFR in this work.
From this perspective, this study produces an illustration
of biological knowledge of molecular interactions from
experimental data.
Conclusions
This study has shown how computational models can be
useful tools for investigating and comparing the bio-
logical behaviour of signal transduction pathways be-
cause they can advance new hypotheses for explaining
the observed biological data and help us to understand
the dynamics with respect to how the pathways function.
Proteins such as GRB2, EGF, SHC1, PTN1, RASA1,
CRK, SRC, PLCG1, STAT3, JAK2, NCK1, GRB10, TGFA,
PTN11, SH3K1, P85A, STAT1, VAV2, STAT5A, SOS1,
PTN6, CBL, PTPN1, UBC, ERBB2, PLCG1, ERRFI1,
EPS15, PTPN11, EREG, BTC, and PTPN6, which are co-
expressed with EGFR, are required to maintain the func-
tional status of the cell environment. The correlation of
EGFR with proteins such as HIF1-α, DLL1, DLL3, FLK1,
Glut5, Bcl-2 and PDGFR-β, which are involved in cell
survival and cell proliferation in RCC, should not be
ignored.
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